专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20220235125A1 Method of Treating Dupuytren's Disease Using A Pre-filled Syringe 有权
公开(公告)号：US20220235125A1
公开(公告)日：2022-07-28
申请号：US17721106
申请日：2022-04-14
申请人： 180 Therapeutics LP
发明人： Jagdeep Nanchahal , Glenn R. Larsen , Marc Feldmann
IPC分类号： C07K16/24
摘要： The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method.

2. 发明申请

US20180036404A1 METHOD OF TREATING A LOCALIZED FIBROTIC DISORDER USING A TNF RECEPTOR 2 ANTAGONIST 审中-公开
公开(公告)号：US20180036404A1
公开(公告)日：2018-02-08
申请号：US15555030
申请日：2016-02-29
申请人： Glenn Larsen , Jagdeep Nanchahal , Marc Feldmann
发明人： Glenn Larsen , Jagdeep Nanchahal , Marc Feldmann
IPC分类号： A61K39/395 , A61K38/19
CPC分类号： A61K39/395 , A61K9/00 , A61K9/0019 , A61K9/0053 , A61K31/00 , A61K31/713 , A61K38/193 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , A61P43/00 , C07K16/241 , C07K16/244 , C07K16/2863 , C07K16/2878 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/55 , C07K2317/622 , C07K2317/76 , C07K2319/30 , C12N15/1136 , C12N2310/14 , C12N2310/531 , C12N2320/31 , C12N2320/35
摘要： The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient. The invention additionally provides a method of treating a patient suffering from liver fibrosis of lung fibrosis which comprises administering to the patient an amount of a TNFR2 antagonist effective to treat the patient.

3. 发明申请

US20190202907A1 METHOD OF TREATING SYSTEMIC FIBROTIC DISORDERS USING AN IL-33/TNF BISPECIFIC ANTIBODY 审中-公开
公开(公告)号：US20190202907A1
公开(公告)日：2019-07-04
申请号：US16329013
申请日：2017-08-31
申请人： 180 Therapeutics LP
发明人： Jagdeep Nanchahal , Glenn R. Larsen , Marc Feldmann
IPC分类号： C07K16/24 , C07K16/28 , A61K31/7105 , A61K39/395 , C12N15/115 , C12N15/113 , C07K16/46
CPC分类号： C07K16/244 , A61K31/7088 , A61K31/7105 , A61K38/1793 , A61K39/395 , A61K39/3955 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K14/54 , C07K14/7155 , C07K16/24 , C07K16/241 , C07K16/2878 , C07K16/46 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/60 , C07K2317/71 , C07K2317/76 , C07K2319/33 , C12N15/1136 , C12N15/115 , C12N2310/11 , C12N2310/14 , C12N2310/16
摘要： The subject invention provides a method of treating a patient suffering from a systemic fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The invention also provides a method of treating a patient suffering from a systemic fibrotic condition which comprises administering to the patient an amount of a bispecific antibody comprising an IL-33 antigen binding domain of which (i) binds to and inhibits activation of, an IL-33 receptor, or (ii) specifically binds to IL-33 and inhibits IL-33 from binding to the IL-33 receptor, and a TNF antigen binding domain of which (i) binds to and inhibits activation of, a TNF receptor, or (ii) specifically binds to TNF and inhibits TNF from binding to the TNF receptor, wherein the bispecific antibody is effective to treat the patient.

4. 发明授权

US11613570B2 Method of treating dupuytren's disease using a pre-filled syringe 有权
公开(公告)号：US11613570B2
公开(公告)日：2023-03-28
申请号：US17721106
申请日：2022-04-14
申请人： 180 Therapeutics LP
发明人： Jagdeep Nanchahal , Glenn R. Larsen , Marc Feldmann
IPC分类号： A61K39/395 , C07K16/24 , A61K39/00
摘要： The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method.

5. 发明申请

US20180030130A1 METHOD OF TREATING A LOCALIZED FIBROTIC DISORDER USING AN IL-33 ANTAGONIST 审中-公开
公开(公告)号：US20180030130A1
公开(公告)日：2018-02-01
申请号：US15555027
申请日：2016-02-29
申请人： Glenn Larsen , Jagdeep Nanchahal , Marc Feldmann
发明人： Glenn Larsen , Jagdeep Nanchahal , Marc Feldmann
IPC分类号： C07K16/24 , A61K9/00 , A61K39/395 , A61K45/06 , C12N15/113 , A61K31/713
CPC分类号： A61K39/395 , A61K9/00 , A61K9/0019 , A61K9/0053 , A61K31/00 , A61K31/713 , A61K38/193 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , A61P43/00 , C07K16/241 , C07K16/244 , C07K16/2863 , C07K16/2878 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/55 , C07K2317/622 , C07K2317/76 , C07K2319/30 , C12N15/1136 , C12N2310/14 , C12N2310/531 , C12N2320/31 , C12N2320/35
摘要： The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient.

6. 发明申请

US20210386855A1 METHOD OF TREATING A LOCALIZED FIBROTIC DISORDER USING A TNF RECEPTOR 2 ANTAGONIST 有权
公开(公告)号：US20210386855A1
公开(公告)日：2021-12-16
申请号：US17388967
申请日：2021-07-29
申请人： 180 Therapeutics LP
发明人： Glenn Larsen , Jagdeep Nanchahal , Marc Feldmann
IPC分类号： A61K39/395 , A61K38/19 , A61P43/00 , C07K16/28 , A61K31/00 , A61K9/00 , A61K31/713 , A61K45/06 , C07K16/24 , C12N15/113
摘要： The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient. The invention additionally provides a method of treating a patient suffering from liver fibrosis of lung fibrosis which comprises administering to the patient an amount of a TNFR2 antagonist effective to treat the patient.

7. 发明申请

US20210040196A1 METHOD OF TREATING EARLY STAGE DUPUYTREN'S DISEASE 有权
公开(公告)号：US20210040196A1
公开(公告)日：2021-02-11
申请号：US16089234
申请日：2017-04-06
申请人： 180 THERAPEUTICS LP
发明人： Jagdeep NANCHAHAL , Glenn R. LARSEN , Marc FELDMAN
IPC分类号： C07K16/24
摘要： The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method.

8. 发明申请

US20200338193A1 METHOD OF TREATING A LOCALIZED FIBROTIC DISORDER USING AN IL-33 ANTAGONIST 审中-公开
公开(公告)号：US20200338193A1
公开(公告)日：2020-10-29
申请号：US16707631
申请日：2019-12-09
申请人： 180 Therapeutics LP
发明人： Glenn Larsen , Jagdeep Nanchahal , Marc Feldmann
IPC分类号： A61K39/395 , A61K38/19 , A61P43/00 , C07K16/28 , A61K31/00 , A61K9/00 , A61K31/713 , A61K45/06 , C07K16/24 , C12N15/113
摘要： The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient.

9. 发明申请

US20160158325A1 METHOD OF TREATING FIBROPROLIFERATIVE DISORDERS INCLUDING DUPUYTREN'S DISEASE WITH ONE OR MORE SPECIFIC HUMAN MATRIX METALLOPROTEINASE AND A TNF ANTAGONIST 审中-公开
标题翻译：一种或多种特异性人类基质金属蛋白酶和TNF拮抗剂治疗包括DUPUYTREN疾病的纤维化疾病的方法
公开(公告)号：US20160158325A1
公开(公告)日：2016-06-09
申请号：US14904391
申请日：2014-07-09
申请人： Glenn LARSEN
发明人： Glenn Larsen
IPC分类号： A61K38/48 , A61K9/00 , A61K45/06
CPC分类号： A61K38/4886 , A61K9/0014 , A61K38/48 , A61K45/06 , C12Y304/24007
摘要： The subject invention also provides a method of treating a subject afflicted with a fibroproliferative disorder comprising periodically administering to the patient an amount of one or more human matrix metalloproteinase, wherein the one or more human matrix metalloproteinase are selected from human metalloproteinase-1 (MMP-1), human metalloproteinase-2 (MMP-2), human metalloproteinase-3 (MMP-3), human metalloproteinase-7 (MMP-7), human metalloproteinase-8 (MMP-8), human metalloproteinase-9 (MMP-9), human metalloproteinase-10 (MMP-10), human metalloproteinase-11 (MMP-11), metalloproteinase-12 (MMP-12), and human metalloproteinase-13 (MMP-13), and wherein the amount is effective to treat the subject. In an embodiment, the invention further comprises periodically administering to the subject an amount of TNF antagonist, wherein the amount of one or more the human matrix metalloproteinase and the amount of TNF antagonist when taken together are effective to treat the subject.
摘要翻译：本发明还提供了治疗患有纤维增生性疾病的受试者的方法，其包括向所述患者定期施用一定量的一种或多种人基质金属蛋白酶，其中所述一种或多种人基质金属蛋白酶选自人金属蛋白酶-1（MMP- 1），人金属蛋白酶-2（MMP-2），人金属蛋白酶-3（MMP-3），人金属蛋白酶-7（MMP-7），人金属蛋白酶-8（MMP-8），人金属蛋白酶-9（MMP- 9），人金属蛋白酶-10（MMP-10），人金属蛋白酶-11（MMP-11），金属蛋白酶-12（MMP-12）和人金属蛋白酶13（MMP-13），其中，对待主题。在一个实施方案中，本发明还包括向受试者周期性施用一定量的TNF拮抗剂，其中一个或多个人基质金属蛋白酶的量和TNF拮抗剂的量合并在一起有效治疗受试者。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式